Get the Stockscreener App
6.18
5.28%
0.31
After Hours:
6.20
0.02
+0.32%
Minerva Neurosciences Inc stock is traded at $6.18, with a volume of 294.68K.
It is up +5.28% in the last 24 hours and down -21.07% over the past month.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
See More
Previous Close:
$5.87
Open:
$6.08
24h Volume:
294.68K
Relative Volume:
1.31
Market Cap:
$267.44M
Revenue:
-
Net Income/Loss:
$-293.42M
P/E Ratio:
-0.2306
EPS:
-26.8031
Net Cash Flow:
$-13.51M
1W Performance:
+14.02%
1M Performance:
-21.07%
6M Performance:
+146.22%
1Y Performance:
+318.98%
1-Day Range:
$5.80
$6.65
1-Week Range:
$5.13
$6.65
52-Week Range:
$1.30
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
6.18 | 254.02M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com India
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences sets June 2026 date for annual stockholder meeting By Investing.com - Investing.com Australia
Minerva Neurosciences sets June 2026 date for annual stockholder meeting - Investing.com
Minerva Neurosciences sets June 3, 2026 annual meeting; stockholder notice deadlines announced - TradingView — Track All Markets
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan
Ideas Watch: Is Minerva Neurosciences Inc stock a hidden gemPortfolio Gains Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - Investing.com
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - Stock Titan
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV - MarketBeat
NERV Technical Analysis & Stock Price Forecast - Intellectia AI
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Tr - GuruFocus
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Treatment - GuruFocus
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV) - Stock Titan
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice - Stock Titan
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered - Stock Titan
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - The Manila Times
Profit Recap: What is the earnings history of Minerva Neurosciences Inc2026 Bull vs Bear & Detailed Earnings Play Strategies - baoquankhu1.vn
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha
Guidance Update: Can Minerva Neurosciences Inc stock outperform in a bear market2026 Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8% - MarketBeat
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Minerva Neurosciences : Olanzapine added to Roluperidone, in patients with negative symptoms (NS) of schizophrenia - marketscreener.com
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Investing News Network
Minerva Neurosciences Presents Data from its Open-label - globenewswire.com
Market Overview: Can Minerva Neurosciences Inc continue delivering strong returns2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - MarketBeat
[EFFECT] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Minerva Neurosciences, IncCommon Stock (NQ: NERV - markets.chroniclejournal.com
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV) - The Globe and Mail
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):